JP2021514398A - Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 - Google Patents

Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 Download PDF

Info

Publication number
JP2021514398A
JP2021514398A JP2020566546A JP2020566546A JP2021514398A JP 2021514398 A JP2021514398 A JP 2021514398A JP 2020566546 A JP2020566546 A JP 2020566546A JP 2020566546 A JP2020566546 A JP 2020566546A JP 2021514398 A JP2021514398 A JP 2021514398A
Authority
JP
Japan
Prior art keywords
egfr
carbon atoms
treat
pharmaceutical preparation
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514398A5 (https=
JPWO2019164945A5 (https=
Inventor
ナサニエル・エス・グレイ
ドリス・ド・クレルク
ジェボン・ジャン
パシ・ジャンヌ
チリッチ・ト
マイケル・エク
ウンヨン・パク
デイヴィッド・ヘップナー
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド, デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2021514398A publication Critical patent/JP2021514398A/ja
Publication of JP2021514398A5 publication Critical patent/JP2021514398A5/ja
Publication of JPWO2019164945A5 publication Critical patent/JPWO2019164945A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020566546A 2018-02-20 2019-02-20 Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法 Pending JP2021514398A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632798P 2018-02-20 2018-02-20
US62/632,798 2018-02-20
PCT/US2019/018770 WO2019164945A1 (en) 2018-02-20 2019-02-20 Pharmaceutical combinations of egfr inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021514398A true JP2021514398A (ja) 2021-06-10
JP2021514398A5 JP2021514398A5 (https=) 2022-02-25
JPWO2019164945A5 JPWO2019164945A5 (https=) 2022-02-25

Family

ID=67686991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566546A Pending JP2021514398A (ja) 2018-02-20 2019-02-20 Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法

Country Status (6)

Country Link
US (1) US20210077469A1 (https=)
EP (1) EP3755330A4 (https=)
JP (1) JP2021514398A (https=)
AU (1) AU2019225803A1 (https=)
CA (1) CA3088972A1 (https=)
WO (1) WO2019164945A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12377080B2 (en) 2019-06-21 2025-08-05 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
JP7561777B2 (ja) * 2019-06-21 2024-10-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｅｇｆｒ阻害剤
IL326879A (en) 2019-11-11 2026-04-01 Dana Farber Cancer Inst Inc EGFR allosteric inhibitors and methods of using them
CN111592535B (zh) * 2020-06-22 2021-07-20 通化师范学院 一种抗egfr突变的抑制剂eai045的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004383A1 (en) * 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
WO2012129562A2 (en) * 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN103702990B (zh) * 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
EP3445357B1 (en) * 2016-04-22 2021-05-26 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004383A1 (en) * 2015-06-30 2017-01-05 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof

Also Published As

Publication number Publication date
AU2019225803A1 (en) 2020-07-23
EP3755330A4 (en) 2021-11-24
EP3755330A1 (en) 2020-12-30
WO2019164945A1 (en) 2019-08-29
CA3088972A1 (en) 2019-08-29
US20210077469A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
JP2021514400A (ja) Ｅｇｆｒの阻害剤およびその使用法
JP6845165B2 (ja) Ｅｇｆｒ阻害剤およびその使用方法
CN111989332B (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP6921115B2 (ja) サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ４／６の分解および使用法
EP3892272B1 (en) Bifunctional molecules for degradation of egfr and methods of use
JP6921114B2 (ja) サイクリン依存性キナーゼ８（ｃｄｋ８）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ８の分解および使用法
JP7084918B2 (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
JP6959248B2 (ja) 癌治療用の４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−カルボニトリル誘導体
RU2717238C2 (ru) Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
CA2829123C (en) Quinazolinediones and their use
CN113563332B (zh) 作为egfr抑制剂的新的嘧啶和治疗病症的方法
EP3037424B1 (en) Novel quinoline-substituted compound
JP2021512059A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法
CN114057771B (zh) 大环化合物及其制备方法和应用
KR20190012167A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
JP2021514011A (ja) Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
JP2021514398A (ja) Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
JP7335275B2 (ja) Ｅｇｆｒの阻害剤およびその使用法
JP2021514012A (ja) Ｅｇｆｒの分解誘導剤およびその使用法
JP2021514397A (ja) Ｅｇｆｒ阻害剤の組合せ医薬製剤およびその使用法
CN120004864A (zh) 双环化合物，包含其的组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230320

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231016